Europe Human Milk Oligosaccharides Market Size, Share & Industry Trends Analysis Report By Application, By Type (2'FL, 3'FL, 3'SL, and 6'SL), By Concentration (Neutral, and Acidic), By Country and Growth Forecast, 2023 - 2030

The Europe Human Milk Oligosaccharides Market would witness market growth of 22.4% CAGR during the forecast period (2023-2030).

The market is expected to witness significant revenue generation during the forecast period, owing to an increase in application scope in functional food & beverages and infant formula, rapid technological advancement in the product line, rise in health awareness, and rapid development of the dairy industry. HMOs are essential components of human milk that are available in a variety of concentrations and compositions. They are novel ingredients that require regulatory approval. With the upsurge in demand for HMOs, two HMOs have undergone the novel food safety assessment in Europe, resulting in a positive evaluation outcome and approval by the European Commission.

HMOs have been used in infant formula and human milk for a prolonged period. The compositions, however, differ, and HMOs are not found in other foods. The path to the market for new and novel HMOs as a dietary supplement is to have GRAS self-affirmed for use in food and subsequently use it in the same form as a dietary supplement. 2'-O-fucosyllactose, 2'-fucosyllactose, and lacto-N-neotetraose have all received such notices.

The German consumer base is known for its health-conscious preferences. HMO-enriched fresh milk aligns with the trend of seeking functional and health-promoting ingredients, attracting consumers looking for products with added nutritional value. Fresh milk with added HMOs can extend beyond infant nutrition to include products aimed at maternal health during pregnancy and lactation. This expansion broadens the HMOs in dairy products. The aforementioned factors will drive the market growth in this region.

The Germany market dominated the Europe Human Milk Oligosaccharides Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $54,123.6 Thousand by 2030. The UK market is exhibiting a CAGR of 21.3% during (2023 - 2030). Additionally, The France market would experience a CAGR of 23.2% during (2023 - 2030).

Based on Application, the market is segmented into Infant Formula, Functional Food & Beverages, Food Supplements, and Others (Clinical Nutrition & Pharmaceuticals). Based on Type, the market is segmented into 2'FL, 3'FL, 3'SL, and 6'SL. Based on Concentration, the market is segmented into Neutral, and Acidic. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke DSM N.V., BASF SE, Chr. Hansen Holding A/S, DuPont de Nemours, Inc., Nestle S.A, Inbiose NV, Biosynth AG, Abbott Laboratories, Royal FrieslandCampina N.V. and Dextra Laboratories Ltd (ICE S.p.A).

Scope of the Study

Market Segments Covered in the Report:

By Application

• Infant Formula
• Functional Food & Beverages
• Food Supplements
• Others (Clinical Nutrition & Pharmaceuticals)

By Type

• 2'FL
• 3'FL
• 3'SL
• 6'SL

By Concentration

• Neutral
• Acidic

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Koninklijke DSM N.V.
• BASF SE
• Chr.Hansen Holding A/S
• DuPont de Nemours, Inc.
• Nestle S.A
• Inbiose NV
• Biosynth AG
• Abbott Laboratories
• Royal FrieslandCampina N.V.
• Dextra Laboratories Ltd (ICE S.p.A)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free